Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan
Abstract Background To identify the prognosis of Japanese patients with collecting duct carcinoma (CDC). Methods We used a hospital-based cancer registry data in Japan to extract CDC cases that were diagnosed in 2013, histologically confirmed, and determined the first course of treatment. We further...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13572-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585636775723008 |
|---|---|
| author | Shuya Kandori Shuhei Suzuki Kosuke Kojo Bunpei Isoda Takazo Tanaka Satoshi Nitta Masanobu Shiga Yoshiyuki Nagumo Atsushi Ikeda Takashi Kawahara Akio Hoshi Hiromitsu Negoro Bryan J. Mathis Ayako Okuyama Hiroyuki Nishiyama |
| author_facet | Shuya Kandori Shuhei Suzuki Kosuke Kojo Bunpei Isoda Takazo Tanaka Satoshi Nitta Masanobu Shiga Yoshiyuki Nagumo Atsushi Ikeda Takashi Kawahara Akio Hoshi Hiromitsu Negoro Bryan J. Mathis Ayako Okuyama Hiroyuki Nishiyama |
| author_sort | Shuya Kandori |
| collection | DOAJ |
| description | Abstract Background To identify the prognosis of Japanese patients with collecting duct carcinoma (CDC). Methods We used a hospital-based cancer registry data in Japan to extract CDC cases that were diagnosed in 2013, histologically confirmed, and determined the first course of treatment. We further investigated treatment modalities and estimated overall survival (OS) by the Kaplan–Meier method. Results A total of 61 CDC patients were identified. The 5-year OS rate for all CDC patients who were diagnosed in Japan during 2013 was 23.6% (95% CI: 15.0–37.4), with a median OS of 14 months (95% CI: 12–24). The 5-year OS rate for CDC patients at stages I, III, and IV were 53.0% (95% CI: 29.9–94.0), 35.7% (95% CI: 19.8–64.4), and 3.4% (95% CI: 0.5–23.7), respectively. Noteworthy, the 1-year OS for stage IV patients was 27.6% (95% CI: 0.5–23.7) and the median OS was only 5 months (95% CI: 4–12). We further examined the OS for advanced disease according to treatment modalities. The median OS of patients who undertook chemotherapy alone was significantly shorter than patients who undertook surgery alone for advanced disease (4 months [95% CI: 4-NA] vs. 15 months [95% CI: 13–68]; p < 0.001) and surgery-only patients had a similar median OS as surgery-plus-chemotherapy patients (19 months [95% CI: 13-NA]; p < 0.001). Moreover, a multivariable analysis for the OS in advanced disease revealed that surgery-plus-chemotherapy patients had significantly more favorable prognoses (HR 0.21, 95% CI: 0.07–0.57). Conclusions Japanese CDC patients face poor prognoses similar to Western countries, especially in advanced cases that receive only chemotherapy. Surgery appears necessary for advanced disease. |
| format | Article |
| id | doaj-art-5c04909e2dd1499b9fc125b57fe1633c |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-5c04909e2dd1499b9fc125b57fe1633c2025-01-26T12:38:07ZengBMCBMC Cancer1471-24072025-01-012511810.1186/s12885-025-13572-8Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in JapanShuya Kandori0Shuhei Suzuki1Kosuke Kojo2Bunpei Isoda3Takazo Tanaka4Satoshi Nitta5Masanobu Shiga6Yoshiyuki Nagumo7Atsushi Ikeda8Takashi Kawahara9Akio Hoshi10Hiromitsu Negoro11Bryan J. Mathis12Ayako Okuyama13Hiroyuki Nishiyama14Department of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Urology, University of TsukubaDepartment of Cardiovascular Surgery, University of TsukubaInstitute for Cancer Control, National Cancer CenterDepartment of Urology, University of TsukubaAbstract Background To identify the prognosis of Japanese patients with collecting duct carcinoma (CDC). Methods We used a hospital-based cancer registry data in Japan to extract CDC cases that were diagnosed in 2013, histologically confirmed, and determined the first course of treatment. We further investigated treatment modalities and estimated overall survival (OS) by the Kaplan–Meier method. Results A total of 61 CDC patients were identified. The 5-year OS rate for all CDC patients who were diagnosed in Japan during 2013 was 23.6% (95% CI: 15.0–37.4), with a median OS of 14 months (95% CI: 12–24). The 5-year OS rate for CDC patients at stages I, III, and IV were 53.0% (95% CI: 29.9–94.0), 35.7% (95% CI: 19.8–64.4), and 3.4% (95% CI: 0.5–23.7), respectively. Noteworthy, the 1-year OS for stage IV patients was 27.6% (95% CI: 0.5–23.7) and the median OS was only 5 months (95% CI: 4–12). We further examined the OS for advanced disease according to treatment modalities. The median OS of patients who undertook chemotherapy alone was significantly shorter than patients who undertook surgery alone for advanced disease (4 months [95% CI: 4-NA] vs. 15 months [95% CI: 13–68]; p < 0.001) and surgery-only patients had a similar median OS as surgery-plus-chemotherapy patients (19 months [95% CI: 13-NA]; p < 0.001). Moreover, a multivariable analysis for the OS in advanced disease revealed that surgery-plus-chemotherapy patients had significantly more favorable prognoses (HR 0.21, 95% CI: 0.07–0.57). Conclusions Japanese CDC patients face poor prognoses similar to Western countries, especially in advanced cases that receive only chemotherapy. Surgery appears necessary for advanced disease.https://doi.org/10.1186/s12885-025-13572-8Collecting duct carcinomaRenal cell carcinomaHospital-based cancer registryOverall survival |
| spellingShingle | Shuya Kandori Shuhei Suzuki Kosuke Kojo Bunpei Isoda Takazo Tanaka Satoshi Nitta Masanobu Shiga Yoshiyuki Nagumo Atsushi Ikeda Takashi Kawahara Akio Hoshi Hiromitsu Negoro Bryan J. Mathis Ayako Okuyama Hiroyuki Nishiyama Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan BMC Cancer Collecting duct carcinoma Renal cell carcinoma Hospital-based cancer registry Overall survival |
| title | Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan |
| title_full | Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan |
| title_fullStr | Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan |
| title_full_unstemmed | Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan |
| title_short | Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan |
| title_sort | surgery lengthens survival for collecting duct carcinoma analysis of hospital based cancer registry data in japan |
| topic | Collecting duct carcinoma Renal cell carcinoma Hospital-based cancer registry Overall survival |
| url | https://doi.org/10.1186/s12885-025-13572-8 |
| work_keys_str_mv | AT shuyakandori surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT shuheisuzuki surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT kosukekojo surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT bunpeiisoda surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT takazotanaka surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT satoshinitta surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT masanobushiga surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT yoshiyukinagumo surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT atsushiikeda surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT takashikawahara surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT akiohoshi surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT hiromitsunegoro surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT bryanjmathis surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT ayakookuyama surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan AT hiroyukinishiyama surgerylengthenssurvivalforcollectingductcarcinomaanalysisofhospitalbasedcancerregistrydatainjapan |